hydralazine has been researched along with imatinib mesylate in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Candelaria, M; Cervera, E; Cortes, J; Dueñas-González, A; Gonzalez-Fierro, A; Gordillo-Bastidas, D; Labardini, J; López-Navarro, O; Taja-Chayeb, L | 1 |
2 other study(ies) available for hydralazine and imatinib mesylate
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Epigenetic therapy with hydralazine and magnesium valproate reverses imatinib resistance in patients with chronic myeloid leukemia.
Topics: Adult; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Epigenesis, Genetic; Female; Follow-Up Studies; Humans; Hydralazine; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Treatment Outcome; Valproic Acid | 2012 |